Eftilagimod Alpha,Pembrolizumab
Immutep,Merck
['eftilagimod', 'immutep', '$immp']
$immp immutep announces compelling clinical results from phase ii trial utilizing its first-in-class soluble lag-3 protein eftilagimod alpha in 1st line nsclc at sitc 2022 annual meeting | marketscreener 